Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3).

Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemp Clin Trials. 2019 10; 85:105835.

View in: PubMed

subject areas

Adolescent
Anemia, Sickle Cell
Child
Child, Preschool
Clinical Trials, Phase III as Topic
Double-Blind Method
Female
Humans
Male
Multicenter Studies as Topic
Platelet Aggregation Inhibitors
Randomized Controlled Trials as Topic
Research Design

authors with profiles

Miguel Raul Abboud